Digestion, General | March 8, 2016 | Author: The Super Pharmacist
Cirrhosis is scarring of the liver as a result of continuous, long-term liver damage. It is a slow progressing disease in which healthy liver tissue is replaced with scar tissue which blocks the flow of blood through the liver. This slows down the processing of hormones, medication, nutrients and naturally produced toxins that require metabolism and excretion. Cirrhosis can be fatal if left untreated and the liver fails, although treatment can significantly help slow its progression.
There are many causes associated with cirrhosis of the liver. In the Western world, the most prominent are alcohol misuse and long-term hepatitis C infection, although many cases of the disease are also idiopathic (cause unknown). Globally, more than half of all cirrhosis is attributable to Hepatitis B and C, with alcohol consumption accountable for around 20% of all cases
As cirrhosis is largely asymptomatic in its early stages, many individuals only find out that they have cirrhosis when being tested for other medical conditions.
Alcohol-related cirrhosis usually occurs after around 10 years of excessive drinking. Whilst cirrhosis has historically been associated with alcoholism, many heavy social drinkers are also at risk of developing the condition. Women who drink excessively are more susceptible to cirrhosis than men, predominantly as a result of their different body sizes and stature.
Individuals who continue to drink heavily develop cirrhosis over three definable phases of alcohol related liver disease (ALD).
First stage is ‘fatty liver’, a side effect of the liver breaking excessive alcohol down
Second stage is alcoholic hepatitis, leading to inflammation of the liver
Third stage is full cirrhosis, developed by approximately 10% of heavy drinkers
Hepatitis is the inflammation of the liver and hepatitis B, C and D can all cause cirrhosis of the liver.
The hepatitis C virus is most often transmitted through blood to blood contact, such as the sharing of needles that are used to inject drugs. Hepatitis B is vaccine preventable.
The third most prominent cause of cirrhosis is non-alcoholic steatohepatitis (NASH). NASH results in the build up of excess fat in the liver, similarly to ALD. This results in scarring and inflammation which in turn can lead to cirrhosis.
NASH is linked to a wide range of risk factors that are modifiable.
It is associated with a wide range of diseases that have significant lifestyle determinants such as:
Some causes of hepatitis do not have modifiable risk factors. These include:
Cirrhosis of the liver is largely asymptomatic during in its primary stages, as the liver remains able to function during the early phase of the disease. It is only when the liver becomes more damaged that telltale symptoms of the disease begin to manifest. Symptoms begin to show when the liver is no longer able to create enough proteins to help fluid composition in the bloodstream, process waste chemicals or clot blood effectively.
Common symptoms are:
Cirrhosis cannot be cured, but treatment can manage symptoms and stop the disease from progressing to its later stages, particularly when undertaken in conjunction with lifestyle changes.
For people who drink, the reduction of alcohol intake is crucial to improving treatment outcomes.
Hepatitis. For who have hepatitis related cirrhosis, doctors will prescribe either antiviral therapy or steroids to reduce liver cell injury. Much of the research for antiviral therapy focuses predominantly on Hepatitis B (HBV) and Hepatitis C (HCV) related cirrhosis: a retrospective cohort study undertaken in 2014, observing the effect of the antiviral drugs interferon and ribavirin in a cohort of 170 patients, reported improved clinical long-term outcomes.
Almost all antiviral therapy is combination therapy, with the sustained virological response in most patients being somewhere between 30-50%, as evidenced by a wide range of systematic reviews.
Autoimmune hepatitis. Topical corticosteroids are often administered for individuals with autoimmune hepatitis. They can also be prescribed an alternative immunosuppressant. With appropriate treatment that is administered promptly, it is estimated that 80% of patients who receive immunosuppressant therapy can achieve remission and long-term survival.
Hospital treatment. Treatment with corticosteroids or pentoxifylline to reduce inflammation is common. Pentoxifylline is a non-selective phosphodiesterase inhibitor, although there is ongoing concern regarding its effectiveness when administered alone or as an adjunct therapy to steroids. Topical corticosteroids are also well researched, but similar concerns persist regarding their effectiveness. A number of systematic reviews have been conducted to overcome the low statistical power of many trials that have been conducted with a small sample number, although they often provide inconclusive or contradictory results. There are relatively few studies comparing the merits of corticosteroids and pentoxifylline. Of the small number that do exist, a 2014 study undertaken in South Korea that had 120 participants with severe alcoholic hepatitis, found the efficacy of pentoxifylline to be considerably less when compared to a corticosteroid (prednisolone).
The amount of free water in the stomach area can make it very difficult for people with cirrhosis to eat and breathe without complication. Salt reduction is the most effective treatment, although diuretics can also be directed at the cause to ease discomfort. Spironolactone is the most common diuretic used.
Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. (2006). The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide Jour Hepatol. 45 (4): 529–38
Scaglione S, Kliethermes S, Cao G, Shoham D, Durazo R, Luke A, Volk ML. (2014). The epidemiology of cirrhosis in the United States: A population-based study. J Clin Gastroenterol [Epub ahead of print]
Takeuchi M, Takino J, Sakasai-Sakai A, Takata T, Udea T, Tsutsumi M, Hyogo H, Yamagishi S. (2014). Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies. World J Hepatol 27:6(12):880-93
Koppe SW. (2014). Obesity and the liver: non-alcoholic fatty liver disease. Transl Res 164(4):312-22
Hu P, Zhao GD, Li H, Gao T, Li ST, Tang WL, Zhou HJ. (2014). Effects of oral antiviral agents on long-term outcomes of treatment-naive patients with HBV-related decompensated cirrhosis: a retrospective cohort study. Zhongzua Gan Zang Bing Za Zhi 22(11):806-11.
Manns MP, McHutchison JG, Gordon SC, et al. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358:958–65
Fried MW, Shiffman ML, Reddy KR, et al. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 347:975–82
Hadziyannis SJ, Sette H, Jr, Morgan TR, et al. (2004). Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140:346–55
Mieli-Vergani G, Vergani D. (2011). Autoimmune Hepatitis. Nat Rev Gastroenterol Hepatol. 8(6):320-9
Li W, Zheng L, Sheng C, Cheng X, Qing L, Qu S. (2011). Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease. Lipids in Health and Disease 10:49. Available online at http://www.lipidworld.com/content/pdf/1476-511X-10-49.pdf (last accessed 3rd January 2015)
Rada G, Arteaga M. Is pentoxifylline effective in alcoholic hepatitis? Medwave 29:14(6):e6002
Christensen E, Gluud C: Glucocorticoids are ineffective in alcoholic hepatitis: A meta-analysis adjusting for confounding variables. (1995). Gut 37(1):113-118
Mathurin P, Mendenhall CL, Carithers RL, et al. (2002). Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): Individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatology 36:480-487
Park SH, Kim DJ, Kim YS et al. (2014). Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non-inferiority, open trial. J Hepatol 61(4):792-8
Bird G, Lau JYN, Koskinas J, et al: Insulin and glucagon infusion in acute alcoholic hepatitis: a prospective randomized controlled trial. Hepatology 1991:14(6):1097-1101
Trinchet JC, Balkau B, Poupon RE, et al: Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: A multicenter sequential trial. Hepatology 1992;15(1):76-81
Bird GLA, Prach AT, McMahon AD, et al: Randomised controlled double-blind trial of the calcium channel antagonist amlodipine in the treatment of acute alcoholic hepatitis. J Hepatol 1998;28:194-198
Fede G, Germani G, Gluud C, Gurusamy KS, Burroughs AK. (2011). Propylthiouracil for alcoholic liver disease. Cochrane Database Syst Rev 15(6):CD002800
Fogel MR, Sawhney VK, Neal EA, Miller RG, Knauer CM, Gregory PB. (1981). Diuresis in the ascitic patient: a randomized controlled trial of three regimens. J. Clin. Gastroenterol. 3 Suppl 1: 73–8